

November 4, 2021



# DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third quarter 2021 financial results will be released after the markets close on Wednesday, November 10<sup>th</sup>. DiaMedica will host a live conference call on Thursday, November 11<sup>th</sup> at 7:00 AM Central Time to discuss its business update and financial results.

## Conference Call details:

Date: Thursday, November 11, 2021  
Time: 7:00 AM CT / 8:00 AM ET  
Web access: <https://events.g4inc.com/attendee/250819405>  
Dial In: (888) 440-4368  
Conference ID: 4814247

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 18, 2021, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

## ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at [www.diamedica.com](http://www.diamedica.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20211104005276/en/>

Contact:

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

[skellen@diamedica.com](mailto:skellen@diamedica.com)

For Investor Inquiries:  
Tim McCarthy  
Managing Director, LifeSci Advisors, LLC  
[tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

Source: DiaMedica Therapeutics Inc.